Candid Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF revenue cycle automation at $99.5M total ($52.5M Oak HC/FT Series C Feb 2025) growing 250% YoY in 2024; claim tracking and AI denial prevention competing with Waystar for digital health and multi-site provider group RCM automation.
About
Candid Health is a San Francisco-based revenue cycle automation platform — backed with $99.5 million in total funding including a $52.5 million Series C in February 2025 led by Oak HC/FT, following a $29 million Series B in September 2024 led by 8VC — providing healthcare providers with an end-to-end claims automation platform that tracks insurance claims through the full payer adjudication lifecycle, automatically detects and fixes claim errors before and after submission, and provides analytics that improve the touchless claim rate (the percentage of claims that process to payment without any human intervention). Candid Health grew revenue nearly 250% year-over-year in 2024 and is expanding from digital health startups (its initial market) to multi-site provider groups and health systems nationally.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.